A phase 3, open-label, randomized, multicenter, 12 month

Project: Research project

Project Details

Description

A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency
StatusFinished
Effective start/end date10/10/164/1/20

Funding

  • OPKO BIOLOGICS, LTD

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.